BMS 981164

Drug Profile

BMS 981164

Alternative Names: BMS981164; IL-31 mAB - Bristol-Myers Squibb; IL-31 monoclonal antibody - Bristol-Myers Squibb

Latest Information Update: 21 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ZymoGenetics
  • Developer Bristol-Myers Squibb; ZymoGenetics
  • Class Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 31 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atopic dermatitis; Inflammation

Most Recent Events

  • 01 Apr 2015 Bristol-Myers Squibb completes a phase I trial in Atopic dermatitis in United Kingdom (NCT01614756)
  • 16 Apr 2014 Bristol-Myers Squibb initiates enrolment in a phase I trial for Atopic dermatitis in United kingdom (UKCRN13421)
  • 01 Jul 2012 Phase-I clinical trials in Atopic dermatitis in United Kingdom (SC, IV) (NCT01614756)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top